Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,476.01 +0.92 (+0.02%) Dow
39,163.92 -5.60 (-0.01%) Nasdaq
17,899.14 +19.84 (+0.11%) Bitcoin USD
62,623.01 -163.57 (-0.26%) CMC Crypto 200
1,342.11 -2.40 (-0.18%)
REGN Jul 2024 1065.000 call
| Previous close | 18.70 |
| Open | 20.20 |
| Bid | 6.70 |
| Ask | 16.00 |
| Strike | 1,065.00 |
| Expiry date | 2024-07-19 |
| Day's range | 18.70 - 20.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
BenzingaWhat's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or
